Influence of PD‐L1 expression on the efficacy of EGFR‐TKIs in EGFR‐mutant non‐small cell lung cancer
- Resource Type
- article
- Authors
- Si‐Yu Lei; Hai‐Yan Xu; Hong‐Shuai Li; Ya‐Ning Yang; Fei Xu; Jun‐Ling Li; Zhi‐Jie Wang; Pu‐Yuan Xing; Xue‐Zhi Hao; Yan Wang
- Source
- Thoracic Cancer, Vol 14, Iss 24, Pp 2327-2337 (2023)
- Subject
- efficacy
epidermal growth factor receptor
programmed death‐ligand 1
tumor protein 53
tyrosine kinase inhibitors
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
- Language
- English
- ISSN
- 1759-7714
1759-7706
Abstract Background Evidence on the influence of programmed death‐ligand 1 (PD‐L1) expression on the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) in EGFR‐mutant non‐small cell lung cancer (NSCLC) patients is at variance. Methods A single‐center retrospective study was conducted to evaluate the influence of PD‐L1 expression on the efficacy of EGFR‐TKIs for NSCLC patients with EGFR mutation. Clinical information was retrieved from electronic medical records. The patients were divided into three subgroups according to PD‐L1 expression level: PD‐L1